eCite Digital Repository
PD-L1 expression in papillary thyroid cancer with and without lymphocytic thyroiditis: a cross sectional study
Fadia, M and Fookeerah, P and Ali, S and Shadbolt, B and Greenaway, TM and Perampalam, S, PD-L1 expression in papillary thyroid cancer with and without lymphocytic thyroiditis: a cross sectional study, Pathology, 52, (3) pp. 318-322. ISSN 0031-3025 (2020) [Refereed Article]
Crown Copyright © 2020 Published by Elsevier B.V. on behalf of Royal College of Pathologists of Australasia. All rights reserved.
The impact of concurrent autoimmune thyroid disease on the tumour microenvironment and disease progression in papillary thyroid cancer (PTC) is not well understood. Studies evaluating the programmed cell death ligand 1 (PD-L1) tumour expression in PTC have shown variable results, and the effect of lymphocytic thyroiditis (LT) on tumour PD-L1 expression has not been adequately assessed. The main aim of this study was to determine expression of PD-L1 in PTC with and without LT. We examined 81 PTC cases; 28.5% of all reviewed PTC had presence of LT. In PTC specimens without LT, tumour PD-L1 expression was significantly lower compared to PD-L1 expression in PTC with LT, 6.9% vs 39.1%, respectively. Expression of PD-L1 did not differ with PTC stage, even when sub-categorised according to the presence and absence of LT. Utility of PD- L1 expression as a prognostic marker in thyroid cancer needs to be interpreted with caution.
|Item Type:||Refereed Article|
|Keywords:||PD-L, Papillary thyroid cancer, lymphocytic thyroiditis, programmed cell death ligand 1, tumour microenvironment|
|Research Division:||Biomedical and Clinical Sciences|
|Research Group:||Clinical sciences|
|Objective Group:||Clinical health|
|Objective Field:||Treatment of human diseases and conditions|
|UTAS Author:||Greenaway, TM (Dr Tim Greenaway)|
|Web of Science® Times Cited:||7|
Repository Staff Only: item control page